Company Overview and News

HTGC / Hercules Capital, Inc. 8-K (Current Report)


HTGC / Hercules Capital, Inc. 497

497 Table of Contents Index to Financial Statements Filed Pursuant to Rule 497 Registration No. 333-214767 PROSPECTUS SUPPLEMENT (To prospectu

HTGC / Hercules Capital, Inc. POS EX

POS EX As filed with the Securities and Exchange Commission on May 9, 2018 Securities Act File No. 333-214767

AVEO Pharmaceuticals (AVEO) Q1 Loss Wider Than Expected

2018-05-09 zacks
AVEO Pharmaceuticals, Inc. (AVEO - Free Report) reported first-quarter 2018 loss of 8 cents per share, wider than the Zacks Consensus Estimate of a loss of 7 cents but narrower than the year-ago loss of 12 cents. However, excluding gains related to a change in fair value of warrant liability, the company reported a loss of 6 cents per share.

9 Great Income Investments You've Never Heard Of | InvestorPlace

2018-05-08 investorplace
Like income? If you’re reading this, then you likely do. And odds are good you’re more than a little familiar with the usual suspects … utilities stocks like Southern Co (NYSE:SO), or diversified healthcare giant Pfizer Inc. (NYSE:PFE). The former is recession proof, while the latter always seems able to find a market by constantly reinventing its drug portfolio, making them a couple of the best income-producing assets the market has to offer.

Hercules Capital: This 10.1%-Yielding Tech-Based BDC Is A Strong Buy

2018-05-07 seekingalpha
Hercules Capital continues to display an appealing risk-reward combination after the company released solid Q1-2018 results.

Insmed's (INSM) CEO William Lewis on Q1 2018 Results - Earnings Call Transcript

2018-05-04 seekingalpha
Good day, ladies and gentlemen, and welcome to the Insmed First Quarter 2018 Financial Results Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions will be given at that time. [Operator Instructions] As a reminder, this conference is being recorded.

Ares Capital Corp.: This 9.5%-Yielding BDC Is Worth Buying

2018-05-04 seekingalpha
Ares Capital Corp. has strong underwriting practices reflected in low non-accruals, and a debt investment portfolio that accentuates capital preservation.

Hercules Capital, Inc. 2018 Q1 - Results - Earnings Call Slides

2018-05-04 seekingalpha
The following slide deck was published by Hercules Capital, Inc. in conjunction with their 2018 Q1 earnings call.

What's in the Cards for LendingClub (LC) in Q1 Earnings?

2018-05-04 zacks
LendingClub Corporation (LC - Free Report) is slated to announce first-quarter 2018 results on May 8, after the market closes. Its earnings and revenues are projected to grow year over year. In the last reported quarter, the company’s adjusted earnings lagged the Zacks Consensus Estimate. While the fourth quarter witnessed higher revenues, an increase in expenses was the undermining factor. Also, LendingClub does not have an impressive earnings surprise history.

Hercules Capital (HTGC) Q1 Earnings Beat on Higher Revenues

2018-05-04 zacks
Hercules Capital, Inc.’s (HTGC - Free Report) first-quarter 2018 net investment income of 31 cents per share beat the Zacks Consensus Estimate by a penny. Also, the figure was 10.7% above the year-ago quarter level. Results reflected higher revenues, growth in investment portfolio and decrease in operating expenses. However, a fall in net asset value was an undermining factor. Distributional Net Operating Income came in at $28.

Hercules Capital's (HTGC) CEO Manuel Henriquez on Q1 2018 Results - Earnings Call Transcript

2018-05-04 seekingalpha
Good day, ladies and gentlemen, and welcome to the Hercules Capital Q1 2018 Earnings Conference Call. At this time, all participants are in a listen-only mode. Later we will conduct a question-and-answer session and instruction will follow at that time. [Operator Instructions] As a reminder, this conference call is being recorded.

HTGC / Hercules Capital, Inc. FORM 8-K (Current Report)


HTGC / Hercules Capital, Inc. 10-Q (Quarterly Report)

htgc-10q_20180331.htm p

Hercules Capital: This 5.25% Baby Bond Has Begun Trading On The NYSE

2018-05-03 seekingalpha
Comparison with all other baby bonds that pay a fixed rate and have less than 10 years to maturity.

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

16h - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

17h - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

CUSIP: 427096870